Semaglutide's 7-day half-life and surgical washout: what's accurate?

What did @doutorakamila actually say?

The caption, not the transcript, carries the actual medical claim here. @doutorakamila stated that "7 dias é a meia vida do medicamento" (7 days is the half-life of the medication) and that because the remaining concentration "pode fazer algum efeito" (can still have some effect), she recommends suspending the medication "3 semanas antes de um procedimento" (3 weeks before a procedure). The video transcript itself appears to be a garbled auto-translation that bears no relationship to the medical topic, so this fact-check focuses on the caption claims, which are the ones reaching 157,800 viewers.

The creator is speaking specifically about GLP-1 receptor agonists, almost certainly semaglutide given the emagrecimento (weight loss) hashtag context and the seven-day half-life figure she cites. This is a clinically relevant topic. People on these medications are routinely scheduled for elective surgeries, endoscopies, and other procedures, and the question of when to stop is genuinely unsettled.

Does the science back this up?

The seven-day half-life for semaglutide is correct. The three-week pause recommendation is reasonable but not universally agreed upon, and the reasoning she gives, while simplified, is directionally accurate.

Semaglutide's half-life of approximately 165 to 168 hours (roughly seven days) is well-established in pharmacokinetic data from the PIONEER and SUSTAIN trial programs and confirmed in the prescribing information for both Ozempic and Wegovy. After one half-life, plasma concentration drops by 50 percent. After two half-lives (14 days), it's at 25 percent. After three half-lives (21 days), roughly 12.5 percent remains. @doutorakamila's logic that "the half that's still circulating can have some effect" is pharmacologically sound. That residual drug activity is exactly why anesthesiologists worry about aspiration risk.

The American Society of Anesthesiologists (ASA) issued guidance in 2023 recommending that patients on weekly GLP-1 agonists hold the dose for one week before elective procedures. The three-week hold @doutorakamila describes is more conservative than the ASA's minimum, which isn't necessarily wrong. Some surgical teams, particularly those doing upper GI procedures, do prefer the longer washout.

What did they get wrong (or right)?

She got the pharmacokinetics right. She got the clinical rationale right. Where things get incomplete is that she doesn't specify which procedure type, which drug, or which patient population she's talking about.

The half-life figure applies accurately to semaglutide (Ozempic, Wegovy) but not to all GLP-1 agonists. Liraglutide (Saxenda, Victoza) has a half-life of roughly 13 hours. Tirzepatide (Mounjaro, Zepbound) has a half-life of approximately five days. Recommending a three-week hold based on semaglutide kinetics for someone on liraglutide would be overly restrictive. She doesn't make this distinction, which matters when your audience is 157,000 people who may be on different agents.

She also doesn't explain why the pause matters clinically. The concern is gastroparesis-like gastric slowing that GLP-1 agonists can induce, raising aspiration risk under general anesthesia, not the GLP-1 activity itself causing surgical complications. Joshi et al. (2023, Anesthesia and Analgesia) documented cases of pulmonary aspiration in patients on GLP-1 agonists who had fasted appropriately. That mechanistic context would have made her advice more actionable.

What should you actually know?

If you're on a GLP-1 agonist and have a procedure scheduled, the hold period depends on which drug you're taking, not a single universal rule.

• Semaglutide (weekly injection): The ASA 2023 guidance recommends holding one week before elective procedures. More conservative teams ask for two to three weeks. Both positions have clinical logic behind them.
• Tirzepatide (weekly injection): Similar guidance applies given its five-day half-life, though specific society statements for tirzepatide are still catching up.
• Liraglutide (daily injection): A shorter hold is typically sufficient given its 13-hour half-life.
• The primary risk is aspiration from delayed gastric emptying, not direct drug toxicity. Even with adequate fasting, residual gastric contents have been found in patients on these agents (Joshi et al., 2023).
• Do not stop your medication based on a social media video. Your prescribing doctor and your anesthesiologist need to make this call together, with knowledge of your full medication list and procedure type.

The three-week figure @doutorakamila cites is not dangerous advice for semaglutide users. But framing it as a universal rule across all GLP-1 medications, without specifying the aspiration mechanism or deferring to the patient's care team, leaves important gaps for a lay audience making real decisions.